Methylated DNA for monitoring tumor growth and regression: How do we get there?

References

• Soletormos G, Duffy MJ, Hayes DF, et al. Design of tumor biomarker-monitoring trials: a proposal by the European group on tumor markers. Clin Chem 2013;59:52–9
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline. Eur J Cancer 2009;45:228–47
   PubMed Web of Science ®Google Scholar
• Fleischer M, Dnistrian AM, Sturgeon CM, et al. Practice Guidelines and Recommendations for use of tumor markers. In: Diamandis EP, Fritsche HA, Lilja H, et al. eds. Tumor markers: physiology, pathobiology, technology and clinical applications. Washington: AACC Press, 2002:33–63
   Google Scholar
• Simera I, Moher D, Hoey J, et al. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35–53
   PubMed Web of Science ®Google Scholar
• Sturgeon CM, Duffy MJ, Stenman UH, et al. National academy of clinical biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008;54:e11–79
   PubMed Web of Science ®Google Scholar
• Ehrlich M, Gama-Sosa MA, Huang LH, et al. Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells. Nucleic Acids Res 1982;10:2709–21
   PubMed Web of Science ®Google Scholar
• Gama-Sosa MA, Slagel VA, Trewyn RW, et al. The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res 1983;11:6883–94
   PubMed Web of Science ®Google Scholar
• Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Dev 2011;25:1010–22
   PubMed Web of Science ®Google Scholar
• Fernandez AF, Assenov Y, Martin-Subero JI, et al. A DNA methylation fingerprint of 1628 human samples. Genome Res 2012;22:407–19
   PubMed Web of Science ®Google Scholar
• Dedeurwaerder S, Desmedt C, Calonne E, et al. DNA methylation profiling reveals a predominant immune component in breast cancers. EMBO Mol Med 2011;3:726–41
   PubMed Web of Science ®Google Scholar
• Dulaimi E, Hillinck J, Ibanez de Caceres I, et al. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res 2004;10:6189–93
   PubMed Web of Science ®Google Scholar
• Matuschek C, Bolke E, Lammering G, et al. Methylated APC and GSTP1 genes in serum DNA correlate with the presence of circulating blood tumor cells and are associated with a more aggressive and advanced breast cancer disease. Eur J Med Res 2010;15:277–86
   PubMed Web of Science ®Google Scholar
• Fackler MJ, McVeigh M, Evron E, et al. DNA methylation of RASSF1A, HIN-1, RAR-beta, cyclin D2 and twist in in situ and invasive lobular breast carcinoma. Int J Cancer 2003;107:970–5
   PubMed Web of Science ®Google Scholar
• Fackler MJ, Malone K, Zhang Z, et al. Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin Cancer Res 2006;12:3306–10
   PubMed Web of Science ®Google Scholar
• Evron E, Dooley WC, Umbricht CB, et al. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet 2001;357:1335–6
   PubMed Web of Science ®Google Scholar
• Krassenstein R, Sauter E, Dulaimi E, et al. Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clin Cancer Res 2004;10:28–32
   PubMed Web of Science ®Google Scholar
• Hibi K, Taguchi M, Nakayama H, et al. Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. Clin Cancer Res 2001;7:3135–8
   PubMed Web of Science ®Google Scholar
• Wong IH, Lo YM, Zhang J, et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res 1999;59:71–3
   PubMed Web of Science ®Google Scholar
• Kersting M, Friedl C, Kraus A, et al. Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J Clin Oncol 2000;18:3221–9
   PubMed Web of Science ®Google Scholar
• Rosas SL, Koch W, da Costa Carvalho MG, et al. Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res 2001;61:939–42
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Nakayama T, Kajita M, et al. Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARbeta2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay. Breast Cancer Res Treat 2012;132:165–73
   PubMed Web of Science ®Google Scholar
• Suh CI, Shanafelt T, May DJ, et al. Comparison of telomerase activity and GSTP1 promoter methylation in ejaculate as potential screening tests for prostate cancer. Mol Cell Probes 2000;14:211–17
   PubMed Web of Science ®Google Scholar
• Hoque MO, Feng Q, Toure P, et al. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol 2006;24:4262–9
   PubMed Web of Science ®Google Scholar
• Dominguez G, Carballido J, Silva J, et al. p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Clin Cancer Res 2002;8:980–5
   PubMed Web of Science ®Google Scholar
• Martins AT, Monteiro P, Ramalho-Carvalho J, et al. High RASSF1A promoter methylation levels are predictive of poor prognosis in fine-needle aspirate washings of breast cancer lesions. Breast Cancer Res Treat 2011;129:1–9
   Google Scholar
• Ibanez de Caceres I, Battagli C, Esteller M, et al. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res 2004;64:6476–81
   PubMed Web of Science ®Google Scholar
• Lenhard K, Bommer GT, Asutay S, et al. Analysis of promoter methylation in stool: A novel method for the detection of colorectal cancer. Clin Gastroenterol Hepatol 2005;3:142–9
   PubMed Web of Science ®Google Scholar
• Chalitchagorn K, Shuangshoti S, Hourpai N, et al. Distinctive pattern of LINE-1 methylation level in normal tissues and the association with carcinogenesis. Oncogene 2004;23:8841–6
   PubMed Web of Science ®Google Scholar
• Torano EG, Petrus S, Fernandez AF, et al. Global DNA hypomethylation in cancer: review of validated methods and clinical significance. Clin Chem Lab Med 2012;50:1733–42
   PubMed Web of Science ®Google Scholar
• Gifford G, Paul J, Vasey PA, et al. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 2004;10:4420–6
   PubMed Web of Science ®Google Scholar
• Sugita H, Iida S, Inokuchi M, et al. Methylation of BNIP3 and DAPK indicates lower response to chemotherapy and poor prognosis in gastric cancer. Oncol Rep 2011;25:513–18
   PubMed Web of Science ®Google Scholar
• Miyake T, Nakayama T, Naoi Y, et al. GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER-negative breast cancer. Cancer Sci 2012;103:913–20
   PubMed Web of Science ®Google Scholar
• Esteller M, Hamilton SR, Burger PC, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999;59:793–97
   PubMed Web of Science ®Google Scholar
• Raguz S, Adams C, Masrour N, et al. Loss of O(6)-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells. Biochem Pharmacol 2013;85:186–96
   Google Scholar
• Jeschke J, O’Hagan HM, Zhang W, et al. Frequent inactivation of cysteine dioxygenase type 1 contributes to survival of breast cancer cells and resistance to anthracyclines. Clin Cancer Res 2013;19:3201–11
   PubMed Web of Science ®Google Scholar
• Bidart JM, Thuillier F, Augereau C, et al. Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem 1999;45:1695–707
   PubMed Web of Science ®Google Scholar
• Kiang DT, Greenberg LJ, Kennedy BJ. Tumor marker kinetics in the monitoring of breast cancer. Cancer 1990;65:193–9
   PubMedGoogle Scholar
• Cler L, Bu D, Lewis C, Euhus D. A comparison of five methods for extracting DNA from paucicellular clinical samples. Mol Cell Probes 2006;20:191–6
   PubMed Web of Science ®Google Scholar
• Hayatsu H, Wataya Y, Kai K, et al. Reaction of sodium bisulfite with uracil, cytosine, and their derivatives. Biochemistry 1970;9:2858–65
   PubMed Web of Science ®Google Scholar
• Hayatsu H, Wataya Y, Kazushige K. The addition of sodium bisulfite to uracil and to cytosine. J Am Chem Soc 1970;92:724–6
   PubMed Web of Science ®Google Scholar
• Pedersen IS, Krarup HB, Thorlacius-Ussing O, et al. High recovery of cell-free methylated DNA based on a rapid bisulfite-treatment protocol. BMC Mol Biol 2012;13:12
   Google Scholar
• Shiraishi M, Hayatsu H. High-speed conversion of cytosine to uracil in bisulfite genomic sequencing analysis of DNA methylation. DNA Res 2004;11:409–15
   PubMed Web of Science ®Google Scholar
• Genereux DP, Johnson WC, Burden AF, et al. Errors in the bisulfite conversion of DNA: Modulating inappropriate- and failed-conversion frequencies. Nucleic Acids Res 2008;36:e150 (1–19)
   PubMed Web of Science ®Google Scholar
• Suzuki T, Ohsumi S, Makino K. Mechanistic studies on depurination and apurinic site chain breakage in oligodeoxyribonucleotides. Nucleic Acids Res 1994;22:4997–5003
   PubMed Web of Science ®Google Scholar
• Munson K, Clark J, Lamparska-Kupsik K, et al. Recovery of bisulfite-converted genomic sequences in the methylation-sensitive QPCR. Nucleic Acids Res 2007;35:2893–903
   PubMed Web of Science ®Google Scholar
• Tanaka K, Okamoto A. Degradation of DNA by bisulfite treatment. Bioorg Med Chem Lett 2007;17:1912–15
   PubMed Web of Science ®Google Scholar
• von Kanel T, Gerber D, Schaller A, et al. Quantitative 1-step DNA methylation analysis with native genomic DNA as template. Clin Chem 2010;56:1098–106
   Google Scholar
• Levenson VV, Melnikov AA. The MethDet: A technology for biomarker development. Expert Rev Mol Diagn 2011;11:807–12
   PubMed Web of Science ®Google Scholar
• Frigola J, Ribas M, Risques RA, et al. Methylome profiling of cancer cells by amplification of inter-methylated sites (AIMS) Nucleic Acids Res 2002;30:e28 (1–7)
   Google Scholar
• Kristensen LS, Hansen LL. PCR-based methods for detecting single-locus DNA methylation biomarkers in cancer diagnostics, prognostics, and response to treatment. Clin Chem 2009;55:1471–83
   PubMed Web of Science ®Google Scholar
• Heichman KA, Warren JD. DNA methylation biomarkers and their utility for solid cancer diagnostics. Clin Chem Lab Med 2012;50:1707–21
   PubMed Web of Science ®Google Scholar
• Egger G, Wielscher M, Pulverer W, et al. DNA methylation testing and marker validation using PCR: Diagnostic applications. Expert Rev Mol Diagn 2012;12:75–92
   PubMed Web of Science ®Google Scholar
• Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821–6
   PubMed Web of Science ®Google Scholar
• Weisenberger DJ, Campan M, Long TI, et al. Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res 2005;33:6823–36
   PubMed Web of Science ®Google Scholar
• Cottrell SE, Distler J, Goodman NS, et al. A real-time PCR assay for DNA-methylation using methylation-specific blockers. Nucleic Acids Res. 2004;32:e10 (1–8)
   PubMedGoogle Scholar
• Dahl C, Guldberg P. A ligation assay for multiplex analysis of CpG methylation using bisulfite-treated DNA. Nucleic Acids Res 2007;35:e144 (1–8)
   Google Scholar
• Serizawa RR, Ralfkiaer U, Dahl C, et al. Custom-designed MLPA using multiple short synthetic probes: Application to methylation analysis of five promoter CpG islands in tumor and urine specimens from patients with bladder cancer. J Mol Diagn 2010;12:402–08
   PubMed Web of Science ®Google Scholar
• Wojdacz TK, Dobrovic A, Hansen LL. Methylation-sensitive high-resolution melting. Nat Protoc 2008;3:1903–8
   PubMed Web of Science ®Google Scholar
• Dahl C, Guldberg P. High-resolution melting for accurate assessment of DNA methylation. Clin Chem 2007;53:1877–8
   Google Scholar
• Worm J, Aggerholm A, Guldberg P. In-tube DNA methylation profiling by fluorescence melting curve analysis. Clin Chem 2001;47:1183–9
   PubMed Web of Science ®Google Scholar
• Diehl F, Schmidt K, Durkee KH, et al. Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology 2008;135:489–98
   PubMed Web of Science ®Google Scholar
• Diehl F, Li M, He Y, et al. BEAMing: Single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods 2006;3:551–9
   PubMed Web of Science ®Google Scholar
• Morrison T, Hurley J, Garcia J, et al. Nanoliter high throughput quantitative PCR. Nucleic Acids Res 2006;34:e123 (1–9)
   PubMed Web of Science ®Google Scholar
• Hindson BJ, Ness KD, Masquelier DA, et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem 2011;83:8604–10
   PubMed Web of Science ®Google Scholar
• Laszlo AH, Derrington IM, Brinkerhoff H, et al. Detection and mapping of 5-methylcytosine and 5-hydroxymethylcytosine with nanopore MspA. Proc Natl Acad Sci USA 2013;110:18904–9
   PubMed Web of Science ®Google Scholar
• Barekati Z, Radpour R, Kohler C, et al. Specificity of methylation assays in cancer research: a guideline for designing primers and probes. Obstet Gynecol Int 2010;2010:870865. doi: 10.1155/2010/870865
   Google Scholar
• Sturgeon CM, Hoffman BR, Chan DW, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin Chem 2008;54:e1–10
   PubMed Web of Science ®Google Scholar
• Sturgeon C. Practice guidelines for tumor marker use in the clinic. Clin Chem 2002;48:1151–9
   PubMed Web of Science ®Google Scholar
• Fraser CG, Hyltoft Petersen P, Libeer JC, et al. Proposals for setting generally applicable quality goals solely based on biology. Ann Clin Biochem 1997;34:8–12
   PubMed Web of Science ®Google Scholar
• Soletormos G, Schioler V, Nielsen D, et al. Interpretation of results for tumor markers on the basis of analytical imprecision and biological variation. Clin Chem 1993;39:2077–83
   PubMed Web of Science ®Google Scholar
• Fraser CG, Hyltoft Petersen P, Larsen ML. Setting analytical goals for random analytical error in specific clinical monitoring situations. Clin Chem 1990;36:1625–8
   PubMed Web of Science ®Google Scholar
• Harris EK, Yasaka T. On the calculation of a “reference change” for comparing two consecutive measurements. Clin Chem 1983;29:25–30
   PubMed Web of Science ®Google Scholar
• Kawakami K, Brabender J, Lord RV, et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 2000;92:1805–11
   PubMed Web of Science ®Google Scholar
• Usadel H, Brabender J, Danenberg KD, et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res 2002;62:371–5
   PubMed Web of Science ®Google Scholar
• Hoque MO, Begum S, Topaloglu O, et al. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res 2004;64:5511–17
   PubMed Web of Science ®Google Scholar
• Muller HM, Millinger S, Fiegl H, et al. Analysis of methylated genes in peritoneal fluids of ovarian cancer patients: a new prognostic tool. Clin Chem 2004;50:2171–3
   Google Scholar
• Hoque MO, Begum S, Topaloglu O, et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst 2006;98:996–1004
   PubMedGoogle Scholar
• Friedrich MG, Weisenberger DJ, Cheng JC, et al. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res 2004;10:7457–65
   PubMed Web of Science ®Google Scholar
• Chan MW, Chan LW, Tang NL, et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 2002;8:464–70
   PubMed Web of Science ®Google Scholar
• Belinsky SA, Palmisano WA, Gilliland FD, et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 2002;62:2370–7
   PubMed Web of Science ®Google Scholar
• Lee TL, Leung WK, Chan MW, et al. Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin Cancer Res 2002;8:1761–6
   PubMed Web of Science ®Google Scholar
• Goessl C, Krause H, Muller M, et al. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res 2000;60:5941–5
   PubMed Web of Science ®Google Scholar
• Sharma G, Mirza S, Parshad R, et al. DNA methylation of circulating DNA: A marker for monitoring efficacy of neoadjuvant chemotherapy in breast cancer patients. Tumour Biol 2012;33:1837–43
   Google Scholar
• Cairns P, Esteller M, Herman JG, et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res 2001;7:2727–30
   PubMed Web of Science ®Google Scholar
• Silva JM, Dominguez G, Garcia JM, et al. Presence of tumor DNA in plasma of breast cancer patients: Clinicopathological correlations. Cancer Res 1999;59:3251–6
   PubMed Web of Science ®Google Scholar
• Palmisano WA, Divine KK, Saccomanno G, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000;60:5954–8
   PubMed Web of Science ®Google Scholar
• Baryshnikova E, Destro A, Infante MV, et al. Molecular alterations in spontaneous sputum of cancer-free heavy smokers: results from a large screening program. Clin Cancer Res 2008;14:1913–19
   PubMed Web of Science ®Google Scholar
• Ahrendt SA, Chow JT, Xu LH, et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst 1999;91:332–9
   PubMed Web of Science ®Google Scholar
• Wong TS, Man MW, Lam AK, et al. The study of p16 and p15 gene methylation in head and neck squamous cell carcinoma and their quantitative evaluation in plasma by real-time PCR. Eur J Cancer 2003;39:1881–7
   PubMed Web of Science ®Google Scholar
• Bearzatto A, Conte D, Frattini M, et al. p16(INK4A) hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer. Clin Cancer Res 2002;8:3782–7
   PubMed Web of Science ®Google Scholar
• Lecomte T, Berger A, Zinzindohoue F, et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer 2002;100:542–8
   PubMed Web of Science ®Google Scholar
• Liggett TE, Melnikov AA, Marks JR, Levenson VV. Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients. Int J Cancer 2011;128:492–9
   PubMed Web of Science ®Google Scholar
• Hoon DS, Spugnardi M, Kuo C, et al. Taback B. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 2004;23:4014–22
   PubMed Web of Science ®Google Scholar
• Fiegl H, Millinger S, Mueller-Holzner E, et al. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res 2005;65:1141–5
   PubMed Web of Science ®Google Scholar
• Avraham A, Uhlmann R, Shperber A, et al. Serum DNA methylation for monitoring response to neoadjuvant chemotherapy in breast cancer patients. Int J Cancer 2012;131:E1166–72
   PubMed Web of Science ®Google Scholar
• Gobel G, Auer D, Gaugg I, et al. Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patients. Breast Cancer Res Treat 2011;130:109–17
   PubMed Web of Science ®Google Scholar
• Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 1997;25:2532–4
   PubMed Web of Science ®Google Scholar